Maxaltlyo

Rizatriptan Benzoate, the active ingredient in Maxaltlyo, is a selective serotonin 5‑HT1B/1D receptor agonist presented as a tablet for oral use. It treats acute migraine attacks with or without aura in adult patients.

GNH USA supplies Maxaltlyo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution. The product complies with European Union marketing authorisation requirements and is manufactured under GMP conditions, ensuring consistent potency and safety for patients across diverse healthcare settings.

Rizatriptan, a selective serotonin 5‑HT1B/1D receptor agonist, is indicated for the acute treatment of migraine.

Migraine with aura: provides rapid relief of headache and associated symptoms when taken at onset. Migraine without aura: reduces pain intensity and duration, helping patients resume normal activities. Acute migraine attacks in adults: aborts migraine episodes and improves functional ability when administered promptly.

Rizatriptan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in fingers or face - Nausea - Dizziness - Dry mouth - Fatigue

Serious or Rare Side Effects: - Serotonin syndrome, especially with other serotonergic agents - Coronary artery vasospasm leading to chest pain or myocardial ischemia - Severe allergic reactions such as anaphylaxis or angioedema - Severe hypertension or hypertensive crisis

Patients should contact healthcare providers promptly if any of these reactions occur.

Before prescribing or taking Maxaltlyo, several precautionary measures should be considered to ensure patient safety.

Cardiovascular assessment: evaluate history of coronary artery disease, uncontrolled hypertension, or cerebrovascular disorders. Concomitant serotonergic drugs: avoid combined use with MAO inhibitors, SSRIs, SNRIs, or other triptans due to serotonin toxicity risk. Pregnancy and lactation: safety has not been established; discuss potential risks with a healthcare professional. Age restrictions: not recommended for children or adolescents under 18 years of age. Drug interactions: review all current medications for potential interactions before initiating therapy. Store at ambient temperature: keep tablets in the original packaging, protect from moisture and light.

Rizatriptan can interact with other medicines; understanding the level of interaction helps guide safe use.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may precipitate serotonin syndrome. - SSRIs, SNRIs, or other triptans: combined serotonergic activity increases risk of severe adverse events. - Ergot derivatives: additive vasoconstrictive effects may lead to coronary spasm.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance blood pressure lowering effects. - Antihypertensive agents: monitor blood pressure for excessive hypotension. - CYP3A4 inhibitors: may increase rizatriptan plasma concentrations.